PRECLINICAL CRO SERVICES FOR DRUGS TARGETING METABOLIC DISORDERS
Physiogenex provides preclinical in vivo and ex vivo CRO services with more than 15 years of expertise in evaluating drugs targeting metabolic disorders such as obesity, diabetes, NASH, fibrosis, diabetic nephropathy, cardiovascular complications, dyslipidemia and atherosclerosis.
We develop in-house and gold standard preclinical models in our cutting-edge facilities near Toulouse, France.
Along with our preclinical CRO services, we offer consulting services adapted to the specific needs of our clients. Our metabolic diseases experts offer their many years of experience in drug development to help you design and run efficient and cost-effective studies to shorten your product’s time to market.
STATE OF THE ART CRO FACILITIES
Physiogenex is located near Toulouse (France) in brand new facilities . Our technical platform is equipped with all appropriate devices to ensure high quality CRO services and reliable study results to our clients.
High success rate customer satisfaction in 2021: 97.5%
When is your turn?
THEY TRUST US
We work with more than 100 biopharmaceutical, nutraceutical and agrifood companies
LATEST NEWS ABOUT PHYSIOGENEX
Physiogenex to present its obese NASH hamster model at the European Incretin Study Group 2022 meeting in Lausanne, Switzerland (Sept. 29th – Oct 1st)
Physiogenex will be presenting the cardiometabolic benefits of the GLP-1 receptor agonist semaglutide in its innovative obese NASH hamster model at the...
Physiogenex to exhibit at booth#D04 and deliver 2 oral presentations at EASD 2022 in Stockholm, Sweden, Sept. 19-23 2022
Physiogenex will be exhibiting at booth#D04 and presenting 2 oral abstracts at the EASD 2022 in Stockholm, Sweden Sept. 19-23. The first oral presentation,...
Physiogenex to present the benefits of intermittent fasting and metformin on NASH and sarcopenia at the 9th Aging Research and Drug Discovery Meeting
Physiogenex will be presenting a new DIO mouse study at the 9th Aging Research and Drug Discovery (ARDD) Meeting in Copenhagen, Denmark, August 30th-September...